Biologic and small molecular agents for simultaneous treatment of psoriasis and psoriatic arthritis: Research progress
10.3724/SP.J.1008.2015.00542
- Author:
Ying LOU
1
Author Information
1. Department of Pharmaceutics, Changhai Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Biologic agents;
Pathogenesis;
Psoriasis;
Psoriatic arthritis;
Small molecule agents
- From:
Academic Journal of Second Military Medical University
2015;36(5):542-547
- CountryChina
- Language:Chinese
-
Abstract:
A quarter of the psoriasis patients develop psoriatic arthritis, and it would be beneficial if a preparation which can be used to treat the skin and joint symptoms at the same time. Currently these biologic agents could serve both include tumor necrosis factor inhibitors such as adalimumab, etanercept, infliximab, golimumab and certolizumab; anti-IL-12/IL-23 p40 antibodies such as ustekinumab; and anti-IL-17 agents such as secukinumab, brodalumab. Recently another group of small molecule agents has been found for the purpose: phosphodiesterase-4 inhibitor, apremilast, JAK inhibitor, tofacitinib and INCBO18424. This review provides an overview on the agents that can be used for the concurrent treatment of skin and joint psoriasis.
